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Background: Heregulin (HRG; also known as neuregulin) is a ligand for ErbB3. One of its isotypes, HRG-β1, binds to
ErbB3 and forms heterodimers with other ErbB family members, thereby enhancing the proliferation and
tumorigenesis of breast cancer cells. HRG stimulation may contribute to the progression of epithelial–mesenchymal
transition (EMT) and tumor metastasis in breast cancer. Majority of studies regarding EMT has been concentrated on
TGF-β signaling. Therefore, we investigated whether the HRG-β1 and ErbB3 activate Smad2 signaling during
process of EMT in breast cancer cells.
Methods: The SK-BR-3 and MCF7 breast cancer cell lines were used. The expressions of phospho-Smad2 and EMT
markers were observed by western blotting and immunofluorescence assays after treatment with HRG-β1. The cell
motility and invasiveness were determined by wound healing and matrigel invasion assays. Smad2 and ErbB3 small
interfering RNA (siRNA) transfections were performed to assess the involvement of ErbB3 and Smad2 in HRG-β1
-induced EMT.
Results: HRG-β1 induced EMT through activation of Smad2. The expression of E-cadherin was decreased after
HRG-β1 treatment, while the expressions of Snail, vimentin, and fibronectin were increased. The HRG-β1-induced
expressions of Snail, vimentin, and fibronectin, and nuclear colocalization of phospho-Smad2 and Snail were
inhibited by pretreatment with a PI3k inhibitor, LY294002, or two phospho-Smad2 inhibitors, PD169316 or
SB203580 and cancer cell migration by HRG-β1 was inhibited. Knockdown of Smad2 by siRNA transfection
suppressed the expressions of Snail and fibronectin in response to HRG-β1 stimulation and knockdown of ErbB3
suppressed the expressions of phospho-Smad2, Snail, and fibronectin induced by HRG-β1, whereas E-cadherin was
increased compared with control siRNA-transfected cells. Knockdown of ErbB3 and Smad2 also decreased SK-BR-3
and MCF7 cell invasion.
Conclusions: Our data suggest that HRG-β1 and ErbB3 induce EMT, cancer cell migration and invasion through the
PI3k/Akt-phospho-Smad2-Snail signaling pathway in SK-BR-3 and MCF7 breast cancer cells.
Keywords: Heregulin, Transforming growth factor-β (TGF-β), Smad2, EMT, Breast cancer, ErbB3, Small interfering
RNA (siRNA)Background
Epithelial–mesenchymal transition (EMT) is a highly
conserved and fundamental process that governs mor-
phogenesis in multicellular organisms. EMT is involved
in both embryonic development and progression of
carcinoma toward dedifferentiated and more malig-
nant states [1]. It is defined by loss of the epithelial* Correspondence: ark@korea.ac.kr
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reproduction in any medium, provided the orphenotype and acquisition of mesenchymal characteris-
tics, such as migratory capacity, loss of polarity, and
cell-to-cell contacts [2]. EMT can contribute to tumor
invasion, metastasis, and resistance to specific chemo-
therapy or hormone therapy.
EMT can be triggered by different signaling molecules,
such as epidermal growth factor (EGF), fibroblast growth
factor, hepatocyte growth factor, transforming growth
factor (TGF)-β, bone morphogenetic proteins, WNTs,
and Notch [3]. Among them, TGF-β is a major inducer
of EMT [4,5]. Binding of TGF-β to its receptor leads to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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form complexes with Smad4 and then translocate into
the nucleus, where they control the transcription of tar-
get genes [6] in collaboration with specific transcription
factors and cofactors such as Snail, Slug, and Zeb1/2
[7,8]. In particular, the role of the Snail family of zinc
finger proteins in EMT and cancer has been highlighted
in several publications [9,10].
Heregulin (HRG; also known as neuregulin) is a mem-
ber of the EGF-like growth and differentiation factors,
and binds with high affinity to the receptors ErbB3 and
ErbB4 [11]. ErbB3, a member of the human epidermal
growth factor receptor (EGFR) family of transmembrane
receptors, undergoes heterodimerization with other
ErbB family members and leads to cell differentiation,
migration, proliferation, and survival [12]. Although four
genes have been identified (HRG1–4), most research in-
terests have focused on the HRG1 gene [13].
HRG-1 has been implicated in normal heart and ner-
vous system development [14] as well as in the patho-
physiological processes of psychiatric diseases, cardiac
diseases, and various types of cancer [15,16]. HRG-1 is
expressed in 30% of human breast cancer patients [17]
and is correlated with poor histological grades [18].
Cheng et al. [19] demonstrated that HRG-β1 induced
EMT through upregulation of Snail via the PI3k/Akt
pathway in the SK-BR-3 cell line. However, the mech-
anism of HRG-β1 and ErbB3 for the regulation of
EMT in breast cancer cells has not been documented
in detail. In this study, we investigated whether HRG-
β1/ErbB3 induces the process of EMT with involve-
ment of Smad2 activation in the ErbB2-overexpressing
SK-BR-3 cell line and luminal A breast cancer cell line
MCF7.
Methods
Cell lines and culture
The human breast cancer cell lines SK-BR-3 and MCF7
were purchased from the American Type Culture Col-
lection (ATCC, Manassas, VA). The cells were
maintained in RPMI-1640 medium (GIBCO, Grand Is-
land, NY) supplemented with 10% fetal bovine serum,
100 U/ml penicillin, and 100 mg/ml streptomycin
(GIBCO). Both cell lines were cultured in a 37°C hu-
midified atmosphere containing 95% air and 5% CO2.
Reagents and antibodies
Recombinant human HRG-β1 (purity: >97%) was pur-
chased from R&D Systems (Minneapolis, MN). It was di-
vided into small aliquots in phosphate-buffered saline (PBS)
and stored at –70°C. The PI3k inhibitor, LY294002 and
phospho-Smad2 pharmacological inhibitors, PD169316 and
SB203580 were purchased from Calbiochem (San Diego,
CA). The inhibitors were dissolved in dimethyl sulfoxide(DMSO). An anti-ErbB3 antibody was purchased from
Santa Cruz Biotechnology Inc. (CA, USA). Anti-phospho
-Smad2 (Ser465/467) and anti-Smad2 antibodies were pur-
chased from Cell Signaling Technology Inc. (Beverly, MO).
An anti-Snail antibody was obtained from Abcam Ltd.
(Cambridge, UK). Anti-E-cadherin and anti-vimentin anti-
bodies were from BD Pharmingen (San Diego, CA). An
anti-fibronectin antibody was obtained from Millipore
(Billerica, MA). A monoclonal anti-β-actin antibody was
obtained from Sigma (St Louis, MO).
Western blotting
Cells were harvested and lysed with RIPA buffer
(20 mM Tris–HCl pH 7.5, 2 mM EDTA, 150 mM NaCl,
1 mM sodium vanadate, 10 mM NaF, 2.5 mM sodium
pyrophosphate, 1% sodium deoxycholate, 0.1% SDS, 1%
NP-40) supplemented with a protease inhibitor (1 mM
phenylmethylsulfonyl fluoride) and a protease inhibitor
cocktail (Roche, Mannheim, Germany). The cell lysates
was cleared by centrifugation at 14,000 rpm for 20 min
at 4°C, and the supernatants were used as total cellular
protein extracts. The protein concentrations were deter-
mined using a BCA protein assay kit (Pierce, Rockford, IL).
The protein lysates were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and then trans-
ferred to polyvinylidene fluoride membranes (Bio-Rad
Laboratories, Hercules, CA). The blocked membranes
with 5% skim milk were incubated with the indicated pri-
mary antibodies, followed by incubation with horseradish
peroxidase-labeled secondary antibodies. Antibody-bound
proteins were detected using the Enhanced Chemilumines-
cence (ECL) reagent (Amersham Biosciences, Piscataway,
NJ) according to the manufacturer's instructions. The
levels of protein expression were quantified using
ImageJ software (NIH, Bethesda, MD) and then nor-
malized by the corresponding expression level in con-
trol cells for each group.
Immunofluorescence
Nuclear translocation of phospho-Smad2 and Snail was
examined by immunofluorescence staining. Approxi-
mately 2 × 104 cells/well were seeded onto 2-well Lab-
Tek II chamber slides (NUNC, Rochester, NY). After
serum starvation, the cells were incubated with HRG-β1
and specific inhibitors. The cells were then washed three
times with PBS and fixed with 4% paraformaldehyde for
10 min. Following three washes with PBS, the cells were
permeabilized with 0.1% Triton X-100 for 20 min. After
washing with PBS, the cells were blocked with 3% bovine
serum albumin for 1 h at room temperature and then in-
cubated with rabbit polyclonal anti-Snail (1:500) and
anti-phospho-Smad2 (1:100) primary antibodies over-
night at 4°C. After three washes with PBS, the cells were
incubated with Alexa Fluor 488-conjugated anti-rabbit
Figure 1 HRG-β1 induces upregulation of the transcription factor Snail and EMT markers in SK-BR-3 cells. (a) The cells were incubated
with 25 ng/ml of HRG-β1 for different times after serum starvation. The expressions of Snail, mesenchymal markers including vimentin and
fibronectin, and epithelial marker E-cadherin were examined by western blotting. β-actin was evaluated as a loading control. Data represent the
means ± SD of three independent experiments. *P < 0.05, significant difference. (b) Immunofluorescence staining of E-cadherin protein. Cells
were treated with or without 25 ng/ml of HRG-β1 for 48 h. The green color represents staining of E-cadherin and the blue color represents
nuclear DNA staining by DAPI (magnification, ×400). The data were analyzed as the percentages of the control cells (**P < 0.01).
Kim et al. BMC Cancer 2013, 13:383 Page 3 of 10
http://www.biomedcentral.com/1471-2407/13/383IgG and Alexa Fluor 594-conjugated anti-goat IgG
secondary antibodies (Invitrogen, Grand Island, NY).
The cells were then washed, mounted with mounting
medium containing DAPI (VECTOR Laboratories,
Burlingame, CA), and observed using an LSM700Figure 2 HRG-β1 induces upregulation of the transcription factor Sna
25 ng/ml of HRG-β1 for different times after serum starvation. The expressi
western blotting. β-actin was evaluated as a loading control. Data represen
significant difference. (b) Immunofluorescence staining of vimentin protein
green color represents staining of vimentin and the blue color represents nconfocal laser scanning microscope (Carl Zeiss, Thornwood,
NY). The expressions of E-cadherin and vimentin were
evaluated with specific antibodies as described above and
incubated with a DyLight 488-conjugated anti-mouse IgG
secondary antibody (VECTOR Laboratories).il and EMT markers in MCF7 cells. (a) The cells were incubated with
ons of Snail, E-cadherin, vimentin, and fibronectin were examined by
t the means ± SD of three independent experiments. *P < 0.05,
. Cells were treated with or without 25 ng/ml of HRG-β1 for 24 h. The
uclear DNA staining by DAPI (magnification, ×200).
Figure 3 HRG-β1 induces phosphorylation of Smad2 in SK-BR-3 (a) and MCF7 (b) cells. (a) After 16 h of serum starvation in serum-free
medium, SK-BR-3 cells were treated with 25 ng/ml of HRG-β1 for the indicated times. Immunoblots were probed with anti-phospho-Smad2 and
anti-Smad2 antibodies. (b) The phosphorylation of Smad2 and total Smad2 were analyzed by western blotting in MCF7 cells. In all cases, β-actin
was evaluated as a loading control. Data represent the means ± SD of three independent experiments. *P < 0.05, significant difference.
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For scratch wound healing assays, cells were seeded into
12-well plates and grown to confluence. After serum star-
vation, the confluent monolayers were scratched with a
plastic tip, washed with PBS to remove the detached cells,
and incubated with HRG-β1 and the indicated inhibitors
for 24 h. The cell migration into the wounded area was
monitored at the indicated time points using a light
microscope (Olympus BX51 Tokyo, Japan). Quantification
of the closure of the monolayers was determined using an
NIH image analysis program and the results were
presented as the relative percentages of wound closureFigure 4 Knockdown of ErbB3 suppresses HRG-β1-induced EMT in SK
siRNAs and treated with 25 ng/ml of HRG-β1 for 24 h. The expressions of E
by western blotting. β-actin was reprobed as a loading control. Data repres
**P < 0.01, significant difference.compared with control monolayers. The assays were re-
peated three times independently.
Matrigel invasion assay
For invasion assay, serum free medium (500 μl) treated
with or without HRG-β1 was added to the lower cham-
bers of a 24 transwell plate (8.0 μm pore size, Corning,
NY) and untransfected or transfected with control (Ctrl),
Smad2 and ErbB3 siRNA cells (2 × 105 cells in 200 μl
medium) were seeded in upper chamber which was coated
with Matrigel (BD Biosciences). After 48 h of incubation,
non-migrating cells were removed with a cotton swab and-BR-3 cells. The cells were transfected with control (Ctrl) or ErbB3
rbB3, E-cadherin, fibronectin, phospho-Smad2, and Snail were analyzed
ent the means ± SD of three independent experiments. *P < 0.05,
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with Diff-Quick Staining kit (Biochemical Sciences,
Swedesboro, NJ). The invaded cells were photographed
randomly with microscope and quantified by counting the
number of cells in three independent experiments.Figure 5 HRG-β1 induces expression of Snail through phospho-Smad
cells were pretreated with vehicle (DMSO) as a control or 10 μM of phosph
and then stimulated with HRG-β1 for 24 h. The inhibition of phospho-Sma
blotting in SK-BR-3 and MCF7 cells. (b) SK-BR-3 cells were pretreated with v
for 24 h. The cells were harvested and immunoblots were analyzed with an
(d) Inhibition of HRG-β1-induced phospho-Smad2 and Snail expressions by
constitutive β-actin expressions in MCF7 cells. Data represent the means ±Small interfering RNA (siRNA) transfection
For transfection, the cells were grown to confluence in 6-
cm plates and a Smad2 siRNA (Santa Cruz Biotechnology
Inc.) and a ErbB3 siRNA at 60 pmol (Santa Cruz Biotech-
nology Inc.) were transfected using a siRNA transfection2 via PI3k/Akt in SK-BR-3 (a, b) and MCF7 (c, d) cells. (a, c) The
o-Smad2 pharmacological inhibitors, PD169316 or SB203580 for 1 h,
d2 by the inhibitors and total Smad2 were analyzed by western
ehicle or 10 μM of LY294002 or PD169316 prior to HRG-β1 stimulation
ti-phospho-Smad2, anti-Smad2, anti-Snail, and anti-β-actin antibodies.
10 μM of LY294002 or SB203580 without affecting total Smad2 and
SD of three independent experiments. *P < 0.05, significant difference.
Figure 6 HRG-β1 induces nuclear colocalization of phospho-
Smad2 and Snail. Immunofluorescence analyses were performed
for the nuclear colocalization of phospho-Smad2 and Snail in SK-BR
-3 cells. Cells were pretreated with vehicle or 10 μM of LY294002 or
PD169316 for 1 h prior to stimulation with 25 ng/ml of HRG-β1.
After incubation for a further 24 h, phospho-Smad2 (red) and Snail
(green) were observed under a confocal laser scanning microscope
and the nuclear DNA was stained with DAPI (blue; magnification,
×200). The lower graphs show the fluorescence intensities of
phospho-Smad2 and Snail as percentages compared with control
cells in three independent experiments involving SK-BR-3 (left) and
MCF7 (right) cells. *P < 0.05, **P < 0.01, significant difference.
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manufacturer’s instructions. A nonspecific siRNA (Santa
Cruz Biotechnology Inc.) was transfected as a control.
After incubation for 6 h, the medium was replaced with
the standard culture medium described above. After an-
other 24 h of incubation, the transfected cells were treated
with HRG-β1 and then used in subsequent evaluations.
Statistical analysis
All experiments were performed in triplicate. The data
were expressed as means ± SD. Statistical analyses were
performed using Student’s t-test. Values of P < 0.05 were
considered to indicate statistical significance.
Results
HRG-β1 induces Snail expression and EMT in SK-BR-3 and
MCF7 cells
Cheng et al. have previously published that Snail is induced
by HRG-β1 in SK-BR-3 cells [19]. As shown in Figure 1a,
HRG-β1 increased the expression of Snail after 2 h and
maintained its expression until 24 h in SK-BR-3 cells. We
identified a few of the common acquired markers during
EMT. Vimentin and fibronectin are commonly used to
identify cells undergoing EMT in cancers. In SK-BR-3 cells,
vimentin and fibronectin were expressed in a time-
dependent manner after HRG-β1 treatment, while E-
cadherin expression was decreased after 48 h of HRG-β1
treatment. We further examined the expression of E-
cadherin by immunofluorescence staining, and found that
E-cadherin was decreased in the HRG-β1-treated cells at
48 h compared with control cells (Figure 1b). In MCF7
cells, the expressions of Snail, vimentin, and fibronectin
were increased after treatment with HRG-β1, while E-
cadherin expression was suppressed at 72 h (Figure 2a). Im-
munofluorescence staining revealed that the expression of
vimentin was increased in HRG-β1-treated cells compared
with control cells (Figure 2b). These findings indicated that
HRG-β1 upregulated Snail, vimentin, and fibronectin and
suppressed E-cadherin in SK-BR-3 and MCF7 cells.
HRG-β1 induces activation of Smad2 in SK-BR-3 and MCF7
cells
We examined the effects of the EGF family peptide
HRG-β1 on the activation of Smad2 phosphorylation.
HRG-β1 at 25 ng/ml induced the phosphorylation of
Smad2 in a time-dependent manner in SK-BR-3 and
MCF7 cells (Figure 3a, b). The level of phospho-Smad2
(Ser465/467) reached its maximum at 2–8 h after treat-
ment and remained for 24 h without affecting the total
Smad2 expression. Commonly, TGF-β1 induces phos-
phorylation of Smad2 within a few minutes of stimula-
tion. Here, we found that HRG-β1 prolonged the
phosphorylation of Smad2 compared with TGF-β1.Knockdown of ErbB3 expression suppresses HRG-β1
-induced EMT in SK-BR-3 cells
As shown in Figure 4, knockdown of ErbB3 expression
by siRNA transfection suppressed the expressions of
phospho-Smad2, Snail, and fibronectin by HRG-β1,
whereas the expression of E-cadherin was increased in
ErbB3 siRNA-transfected cells (ErbB3 siR) compared
with control siRNA-transfected SK-BR-3 cells (Ctrl siR).
On this basis, HRG-β1/ErbB3 signaling induced EMT in
the SK-BR-3 and MCF7 breast cancer cell lines.
HRG-β1 induces expression of Snail through activation of
Smad2 via the PI3k/Akt signaling pathway
First, we identified that HRG-β1-induced Smad2 phos-
phorylation was inhibited by pretreatment with the PI3k
inhibitor LY294002 (data not shown). It is known that
HRG-β1 phosphorylates Smad2 via the PI3k/Akt signal-
ing pathway [19]. Therefore, to investigate the possible
involvement of Smad2 in HRG-β1-induced Snail gene
expression, SK-BR-3 and MCF7 cells were pretreated
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PD169316 and SB203580 [20,21]. PD169316 inhibited
HRG-β1-induced Smad2 phosphorylation in SK-BR-3
cells and SB203580 had a more efficient inhibitory effect
in MCF7 cells (Figure 5a, c). We pretreated the cells
with LY294002, PD169316, or SB203580 alone and com-
binations of LY294002 and PD169316 or SB203580 prior
to HRG-β1 stimulation to both cell types. As shown
in Figure 5b, d, the HRG-β1-induced expressions of
phospho-Smad2 and Snail were inhibited by treatment
with the above inhibitors, indicating that HRG-β1 in-
duced expression of Snail through activation of Smad2
via the PI3k/Akt signaling pathway. Since these Smad2
phosphorylation inhibitors are also known to block p38
phosphorylation, the role of Smad2 was further explored
by the more specific genetic approach of RNA interfer-
ence (siRNA).
HRG-β1 induces nuclear colocalization of phospho-Smad2
and Snail
HRG-β1 treatment for 24 h induced nuclear colocalization
of phospho-Smad2 and Snail in SK-BR-3 cells, and this
translocation to the nucleus was inhibited by pretreatment
with LY294002 and PD169316 before HRG-β1 stimulation
(Figure 6). In MCF7 cells, HRG-β1 induced nuclearFigure 7 HRG-β1 induces EMT through phospho-Smad2-mediated Sn
cells were pretreated for 1 h with vehicle, 10 μM of LY294002, or PD169316
with 25 ng/ml of HRG-β1. The expressions of vimentin and fibronectin wer
ml of HRG-β1 after pretreatment with 10 μM of LY294002 or SB203580 alon
probed with anti-vimentin and anti-fibronectin antibodies. In all cases, β-ac
three independent experiments. *P < 0.05, significant difference.colocalization of phospho-Smad2 and Snail, and pretreat-
ment with LY294002 and SB203580 suppressed the nu-
clear translocation induced by HRG-β1 (data not shown).
The mean percentages of fluorescence of phospho-Smad2
and Snail are also shown in Figure 6.
HRG-β1 induces EMT through phospho-Smad2-mediated
Snail via the PI3k/Akt signaling pathway
As mentioned earlier, HRG-β1 increased the expres-
sions of vimentin and fibronectin during EMT in
SK-BR-3 and MCF7 cells. As shown in Figure 7a, b,
the HRG-β1-induced expressions of vimentin and
fibronectin were inhibited by the indicated inhibi-
tors. Taken together, HRG-β1 induced EMT through
phospho-Smad2-mediated expression of Snail via the
PI3k/Akt signaling pathway in both breast cancer
cell lines.
Knockdown of Smad2 expression suppresses HRG-β1-induced
expressions of Snail and fibronectin
SK-BR-3 and MCF7 cells were transfected with control
and Smad2 siRNAs. As shown in Figure 8a, b, the HRG-
β1-increased expressions of Snail and fibronectin in con-
trol siRNA-transfected cells (Ctrl siR) compared with un-
treated control cells (untreated ctrl) were downregulatedail via PI3k/Akt signaling in SK-BR-3 (a) and MCF7 (b) cells. (a) The
alone or a combination of LY294002 and PD169316 and then treated
e identified by western blotting. (b) The cells were treated with 25 ng/
e or a combination of LY294002 and SB203580. Immunoblots were
tin served as a loading control. Data represent the means ± SD of
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gether, Smad2 activation plays roles in the expression of
Snail and induction of EMT by HRG-β1 in SK-BR-3 and
MCF7 cells.
HRG-β1 and ErbB3 induces cancer cell migration and
invasion through Smad2 activation
We performed in vitro wound healing assays. Pretreat-
ment with LY294002 and PD169316 or SB203580
inhibited the cell migration of SK-BR-3 and MCF7 cells
in the presence of HRG-β1 (Figure 9a, b). In cell inva-
sion assay, knockdown of ErbB3 and Smad2 by siRNA
transfection inhibited the cell invasive ability of SK-BR-3
and MCF7 cells under HRG-β1 stimulation in matrigel-
coated chamber (Figure 9c, d). Collectively, these data
suggested that HRG-β1 induced cancer cell migration
and invasion through induction of EMT via PI3k/Akt-
phospho-Smad2-Snail signaling pathway.
Discussion
Breast cancer is the most common malignancy among
women worldwide. Understanding the mechanisms of
cancer invasion and metastasis is a very important issue
in cancer research. The majority of studies regardingFigure 8 Knockdown of Smad2 suppresses HRG-β1-induced
expressions of Snail and fibronectin in SK-BR-3 (a) and MCF7
(b) cells. (a, b) The cells were transfected with control or Smad2
siRNAs prior to treatment with 25 ng/ml of HRG-β1. After incubation
for a further 24 h, the expressions of phospho-Smad2, Smad2, Snail,
and fibronectin were analyzed by western blotting. β-actin was
reprobed as a loading control. Data represent the means ± SD of
three independent experiments. *P < 0.05, **P < 0.01, significant
difference.EMT have focused on TGF-β signaling in various kinds
of disease settings [5,6,8,22]. Thus far, the basal-like type
and triple-negative type of breast carcinomas are charac-
terized to show mesenchymal and stem-cell features and
are known to be correlated with resistance to therapy
[23,24].
It has been suggested that not only TGF-β but also
various kind of signaling molecules, such as growth fac-
tors, cytokines, integrins, and Wnts, are inducers of
EMT [25]. HRG is a ligand for ErbB3 and ErbB4 and
has also been reported to promote the invasive behavior
of breast cancer cells in vitro [26]. HRG-induced ErbB2/
ErbB3 heterodimers are considered to induce strong
downstream signaling and to activate various biological
responses, such as cellular proliferation, maturation, sur-
vival, apoptosis, and angiogenesis [27-31]. Cheng et al.
[19] demonstrated that HRG-β1 induced EMT through
Snail upregulation via the PI3k/Akt pathway in the
ErbB2-overexpressing SK-BR-3 cell line. Various kinds of
cancer cells, such as breast cancer cells, glial cells, neural
tissues, and hepatocytes, are known to secrete HRG [32].
Although the tumor cells can be stimulated by HRG in
autocrine or paracrine manners, small numbers of circu-
lating tumor cells can be activated by nearby HRG-
secreting organs, such as the liver and central nervous
system, where cancer cells move to and settle down.
Blockade of HRG expression inhibits tumorigenesis and
metastasis of breast cancer cells [33].
In this study, we have obtained evidence that HRG
plays an important role in breast cancer.
It is a novel observation that the induction of EMT by
HRG-β1 via upregulation of Snail involved the Smad2
signaling pathway, which is one of TGF-β signaling mol-
ecules. We found that phospho-Smad2 inhibitors
(PD169316 or SB203580) and Smad2 siRNA transfection
inhibited Snail expression and EMT, which were induced
by HRG-β1. Furthermore, we identified that HRG-β1 in-
duced cancer cell migration and invasion through
Smad2 activation by wound healing assays and matrigel
invasion assays. Overall, HRG-β1 induced EMT through
Snail expression by activation of Smad2 not only in the
SK-BR-3 cell line, but also in the MCF7 cell line, which
expresses ErbB2 at basal levels. This dynamic and re-
versible emergence of the mesenchymal phenotype can
be triggered by a variety of tumor microenvironments in
the non-basal-like phenotypes of breast cancer cell lines.
Activation of RTK signaling caused by HRG-associated
heterodimerization of ErbB3 and ErbB2 may be a critical
step in tumor progression. We identified that the ErbB2
interaction with ErbB3 is required for the HRG-β1-in-
duced EMT process. Specific siRNA transfection is a
useful tool for evaluating the biologic effects of a target
gene. In the presence of HRG-β1, knockdown of ErbB3
resulted in suppression of phospho-Smad2, Snail, and
Figure 9 HRG-β1-induces cancer cell migration and invasion through Smad2 activation in SK-BR-3 (a, c) and MCF7 (b, d) cells. (a, b) The
motility of each cell type was assessed by wound healing assays. A scratch was made across confluent monolayers using a plastic tip and the
cells were then pretreated with 10 μM of LY294002 and PD169316 or SB203580 prior to stimulation with HRG-β1. After 24 h of incubation, the
migrated cells were monitored using a light microscope. Data were analyzed as percentages of the control cells in three independent
experiments. *P < 0.05, significant difference. (c, d) A matrigel invasion assay was used to quantify cell invasion. After 24 h of transfection, the cells
were seeded into upper chambers and incubated for 48 h in the presence of 25 ng/ml of HRG-β1. Then, the cells that invaded into the lower
surface were photographed under a light microscope, with × 200 magnification. Data were analyzed as the percentage of the control of the three
independent experiments. *P < 0.05 and **P < 0.01 were considered significant.
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cadherin was increased in SK-BR-3 cells. Taken together,
ErbB3 contributed to the HRG-β1-induced EMT process
and cell migration through phospho-Smad2-mediated
expression of Snail via the PI3k/Akt signaling pathway
in SK-BR-3 and MCF7 breast cancer cells.
These findings are important for defining the tumori-
genic roles of ErbB receptors and HRG as well as
Smad2 activation in breast cancers, because HRG-β1
can overcome the inhibitory effects of anti-EGFR ther-
apies on cell growth and activate invasion in tamoxifen-
resistant cells through promotion of ErbB3/ErbB2
heterodimerization and activation of the PI3k/Akt sig-
naling pathway [34].Conclusions
In conclusion, we have demonstrated a downstream sig-
nal transduction pathway of HRG-β1-induced EMT that
occurred in the SK-BR-3 and MCF7 breast cancer cell
lines. Therefore, we suggest that blockade of the EMT
mechanisms by HRG, including ErbB3 and not only
Snail but also Smad2, might be a useful therapeutic tar-
get in breast cancer.
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